Peptides DB
Research-centric peptide and protocol reference hub
Study 16 of 17Tesamorelin literatureDrug testing and analysis · Observational2023

Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.

Tesamorelin has a short detection window, with metabolites detectable in serum for up to 2 hours, suggesting that testing should focus on these metabolites rather than intact tesamorelin.

Read at Drug testing and analysisAdd to compare

Where it sits

this study against the rest of the tesamorelin corpus
1
Preclinical
4
Observational · this one
0
Open-label
9
Randomised
3
Reviews

Summary and findings

The study investigated the detection of tesamorelin and its metabolites in human urine and serum after administration. Six healthy volunteers received 10 consecutive days of tesamorelin injections. The study found that intact tesamorelin was detectable in serum for up to 30 minutes and metabolites for up to 2 hours post-injection.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Limit of detection for urine was 13 pg/mL and for serum was 41 pg/mL.n=62023

Abstract

The authors’ words, as Drug testing and analysis supplied them

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue used for reducing excess abdominal fat in HIV-infected patients suffering from lipodystrophy. Together with other GHRH analogues, it is classified as a doping agent and is prohibited at all times according to the World Anti-Doping Agency (WADA). To investigate whether current testing methodologies are adequate for detecting tesamorelin abuse, an administration study was performed involving six healthy volunteers and 10 consecutive days of Egrifta (tesamorelin) injections, mimicking a doping protocol. A validated solid-phase extraction method was used to analyse the samples, reaching limits of detection of 13 pg/mL in urine and 41 pg/mL in serum. To account for the generation of metabolites by proteolytic degradation, tesamorelin was incubated in fresh human serum. Five previously unreported metabolites were found and identified, extending the detectability of tesamorelin abuse. Oxidation of the methionine residue was observed in tesamorelin and metabolites, hence ions to monitor the sulfoxide and sulfone forms were added to the methods. Despite a limit of detection 70 times lower than the WADA minimum required performance level and the inclusion of several metabolites, tesamorelin use could not be detected in post-administration urine. In serum, tesamorelin metabolites were detected in all six volunteers for up to 2 h after injection, whereas intact tesamorelin was detected in just two volunteers, up to 30 min post-administration. The outcome of this study shows that tesamorelin has a short detection window and testing methods should focus on metabolites in serum, rather than intact compounds in urine.

Background

This paper addresses the detection of tesamorelin, a GHRH analogue, in the context of doping regulations. Previous studies have indicated that GHRH analogues are prohibited by the World Anti-Doping Agency. Understanding the pharmacokinetics and detection methods for such substances is crucial for effective monitoring in sports.

Methods

The study involved six healthy volunteers who received daily injections of tesamorelin for 10 consecutive days. A validated solid-phase extraction method was employed to analyze urine and serum samples. The primary outcome was the detection of intact tesamorelin and its metabolites in these samples.

Results

Intact tesamorelin was detected in serum for up to 30 min post-administration in two volunteers. In urine, tesamorelin use could not be detected post-administration. Metabolites were detected in serum for up to 2 h after injection in all six volunteers.

Interpretation

The findings suggest that while tesamorelin and its metabolites can be detected in serum, the short detection window limits the effectiveness of current testing methods. This aligns with prior literature indicating challenges in detecting GHRH analogues. The small sample size and focus on detection rather than broader implications limit the conclusions that can be drawn.

Key findings

  • Limits of detection were 13 pg/mL in urine and 41 pg/mL in serum.
  • Intact tesamorelin was detected in serum for up to 30 min post-administration in two volunteers.
  • Tesamorelin metabolites were detected in all six volunteers for up to 2 h after injection.
  • Tesamorelin use could not be detected in post-administration urine.
  • Five previously unreported metabolites were identified.

Limitations

  • small sample size of six volunteers
  • study focused solely on detection capabilities
  • short follow-up period post-administration
  • not applicable for broader implications of tesamorelin use

Elsewhere in the Tesamorelin corpus

BWeight management in people with HIV.The lancet. HIV · 2015 · Not reported in abstract.reviewBDetecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.Drug testing and analysis · 2026 · Limit of detection of 13 pg/mL in urine and 41 pg/mL in serum.HumanDWeight management in people with HIV.The lancet. HIV · 2026—AEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.The Journal of clinical endocrinology and metabolism · 2010 · -24 +/- 41 cm(2) VAT reduction in tesamorelin vs 2 +/- 35 cm(2) in placebo at 26 wk, P < 0.001.HumanDTesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.The Annals of pharmacotherapy · 2012 · Not reported in abstract.reviewATesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.BMJ open · 2026Human